Aytu BioPharma is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products in areas of high unmet medical need. The company’s core therapeutic areas include urology, endocrinology and respiratory medicine, with an emphasis on products that can benefit from Aytu’s targeted commercial infrastructure. Since its inception, Aytu has pursued a strategy of in-licensing or acquiring late-stage assets with established safety and efficacy profiles, then leveraging its dedicated sales force and distribution network to drive adoption among healthcare providers.
Aytu’s marketed portfolio features several differentiated products. Natesto® is an FDA-approved intranasal testosterone gel for the treatment of male hypogonadism that offers a non-injectable option and avoids first-pass hepatic metabolism. ZolpiMist® is an oral spray formulation of the sedative-hypnotic zolpidem tartrate indicated for short-term insomnia, designed to provide rapid onset with a metered-dose application. Tuzistra® XR is a twice-daily, extended-release codeine-chlorpheniramine cough syrup that combines antitussive and antihistamine effects in a single formulation. The company continues to expand its pipeline through partnerships and licensing arrangements targeting pediatric orphan diseases, endocrine disorders and other areas with significant patient need.
Founded in 2015 and headquartered in Englewood, Colorado, Aytu BioPharma grew through a series of strategic mergers and asset acquisitions. The company established its U.S. commercial infrastructure shortly after formation, recruiting experienced sales and marketing teams to build product awareness among specialists and primary care physicians. Over time, Aytu has added international distribution agreements to extend its reach into Canada, Latin America and select European markets, while maintaining a lean corporate structure that prioritizes commercialization and business development.
Under the leadership of Chief Executive Officer Josh Disbrow and a management team with decades of combined commercial and clinical experience, Aytu BioPharma aims to augment its existing product suite with new acquisitions and in-house development programs. The board and executive group leverage backgrounds in pharmaceutical R&D, regulatory affairs and specialty medicine to identify and advance opportunities that align with the company’s goal of delivering meaningful therapeutic options to patients and value to shareholders.
AI Generated. May Contain Errors.
Free AYTU Stock Alerts